

NOVEMBER 20, 2003

**Minutes of the November 20, 2003
Drug Utilization Review (DUR) Board Meeting**

Members Attending: Tim Alford, M.D., Clarence Dubose, RPh, John Mitchell, M.D., Montez Carter, RPh, Joe McGuffee, RPh, Leigh Ann Ramsey, RPh, Sara Weisenberger, M.D.

Members Absent: Bob Broadus, RPh, Diana McGowan, RPh, Andrea Phillips, M.D., Cynthia Undesser, M.D.,

Also Present: Sam Warman, RPh, Lew Anne Snow, R.N., Kathleen Burns, R.N. -HID
Rica Lewis-Peyton, Judith Clark, Terri Kirby, RPh, Bo Bowen, Phyllis Williams, Gay Gipson, R.N. - DOM, Otis Washington; Program Integrity - DOM

Clarence DuBose, RPh, called the meeting to order at 2:14 p.m.

Approval of minutes of last meeting (September 18, 2003): Joe McGuffee made a motion to accept the minutes as written. Leigh Ann Ramsey seconded the motion. All voted in favor of the approval.

Reports:

Update on the use of Generic Provider ID

Sam Warman presented data which indicated a 38% decrease in the use of the default provider ID after intervention letters were sent to those providers who utilized the default provider ID on greater than 40 % of their total prescriptions. Clarence DuBose asked HID to continue with this study. No recommendations were made.

Pharmacy Program Updates

Judith Clark, Pharmacy Bureau Director of the Division of Medicaid distributed handouts to the board members on the maximum units of inhalants allowed by DOM and a copy of OTC drugs currently covered by DOM. She stated that the P & T Committee voted to allow Prilosec OTC, Alavert, and Claritin Syrup to be covered without requiring prior authorization. Mrs. Clark reported that there is now a new section on the Division of Medicaid website designated specifically to Pharmacy Services. With the implementation of the Envision System on October 5, 2003 maximum units allowed for all medication went into effect. Medicaid provides up to a 34-day supply of medication to Medicaid beneficiaries. First Data Bank provides updated information regarding recommended maximum daily dosing and maximum units allowed to the Division of Medicaid. The maximum daily dose is determined according to the FDA approved and manufacturers suggested recommended daily dose. DOM allows 1.5 or 150% of the recommended maximum daily dose to be processed without triggering and over-ride. Maximum dose limits are utilized as a way to address abuse and over utilization of medications. A maximum dose over-ride request must be submitted to HID. Handouts were presented to the board regarding lab test billing forms, procedures and CPT codes necessary for patients being treated with lipid-lowering agents. DOM does not limit the number of times these lab tests may be performed. In order to be reimbursed for the lab test, the physician must first verify that the Medicaid beneficiary has at least one outpatient visit remaining, and when billing for the lab test, the correct form and CPT codes must be submitted to DOM. The physician's office or independent lab must also be CLIA (clinical laboratory improvement amendments) certified in order to receive payment. No recommendations were made.